Imugene Company Description
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study.
The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer.
Imugene Limited is headquartered in Sydney, Australia.
Contact Details
Address: 4-6 Bligh Street Sydney, NSW 2000 Australia | |
| Phone | 61 2 9423 0881 |
| Website | imugene.com |
Stock Details
| Ticker Symbol | IUGNF |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000IMU9 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Leslie Chong | Chief Executive Officer, MD and Executive Director |
| Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Executive Chairman |
| Darren Michael Keamy B.Com., CPA | Chief Financial Officer and Company Secretary |
| Dr. John Byon M.D., Ph.D. | Chief Medical Officer |
| Ursula McCurry | Chief Clinical Operations Officer |